Muller Alexander J, Scherle Peggy A
Lankenau Institute for Medical Research, Wynnewood, Pennsylvania 19096, USA.
Nat Rev Cancer. 2006 Aug;6(8):613-25. doi: 10.1038/nrc1929.
Cancer immunotherapy has been predominantly focused on biologically based intervention strategies. However, recent advances in the understanding of tumour-host interactions at the molecular level have revealed targets that might be amenable to intervention with small-molecule inhibitors. In particular, key effectors of tumoral immune escape have been identified that contribute to a dominant toleragenic state that is suspected of limiting the successful implementation of treatment strategies that rely on boosting immune function. Within the context of the pathophysiology of cancer-associated immune tolerance, this Review delineates potential molecular targets for therapeutic intervention and the progress that has been made in developing small-molecule inhibitors.
癌症免疫疗法主要集中在基于生物学的干预策略上。然而，最近在分子水平上对肿瘤-宿主相互作用的理解取得的进展揭示了一些可能适合用小分子抑制剂进行干预的靶点。特别是，已经确定了肿瘤免疫逃逸的关键效应因子，这些因子导致了一种占主导地位的致耐受状态，这种状态被怀疑限制了依赖增强免疫功能的治疗策略的成功实施。在癌症相关免疫耐受的病理生理学背景下，本综述阐述了治疗干预的潜在分子靶点以及在开发小分子抑制剂方面取得的进展。
